The backtest results for IPHA's earnings beat are not provided, leaving the impact on the stock's performance unclear. Without specific data on returns or probabilities, it is difficult to assess the effectiveness of trading strategies based on this event.

This lack of information suggests that either the event did not produce significant measurable effects or the data was insufficient for conclusive analysis.

Investors should exercise caution and seek additional data before making decisions based on IPHA's earnings beat.

The backtest results show that IPHA had a 100% win rate with a 1.61% return over 3 days following an earnings miss, but experienced negative returns of -4.36% and -12.40% over 10 and 30 days respectively. This indicates a short-term positive reaction that quickly reverses into significant losses. The maximum return of 8.80% occurred on day 5, suggesting volatility shortly after the event. Investors should be cautious holding IPHA long-term after an earnings miss, as initial gains may be outweighed by subsequent declines.

backtest_data

The backtest results show that the Biotechnology Industry experienced a negative impact following earnings beats, with a maximum return of only 0.24% occurring 15 days after the event. This suggests that despite positive earnings surprises, the sector did not generate significant positive returns in the tested period.

The analysis indicates that earnings beats in this industry do not translate into strong price appreciation, possibly due to market skepticism or other overriding factors.

Investors should be cautious about expecting gains solely based on earnings beats in the Biotechnology Industry and consider additional factors before investing.

The backtest results show that earnings misses in the Biotechnology Industry have no significant impact, with a negligible maximum return of -0.05% observed three days after the event. This indicates that the industry’s stock prices are largely unaffected by earnings misses over the tested period.

The analysis suggests that investors should not expect meaningful price movements in the Biotechnology sector following earnings misses, reflecting market resilience or other overriding factors.

For investment strategies, this implies that earnings misses in this industry may not be a reliable signal for trading decisions.

Backtest IPHA Earning Beats Expectations

Find all upcoming company earnings reports scheduled for mar 26 2026. Get details on which companies are reporting and their expected results.

Calendar